Shuanzhu Zhai

Title: Innovations by Shuanzhu Zhai in Biotechnology

Introduction

Shuanzhu Zhai is a notable inventor based in Tianjin, China. He has made significant contributions to the field of biotechnology, particularly in the development of diagnostic tools. His work focuses on improving the detection of specific antigens, which is crucial for timely medical interventions.

Latest Patents

Shuanzhu Zhai holds a patent for a GM hybridoma cell, monoclonal antibody, kit, and preparation method and use thereof. This invention provides a hybridoma cell under the accession number CGMCC No. 13827. The hybridoma cell is capable of producing a monoclonal antibody against galactomannan antigen. The kit developed from this invention can specifically bind to the GM antigen, demonstrating both sensitivity and specificity of over 95%. It has a detection limit of 0.85 ng/mL, which is an improvement over existing products. This innovation allows for early detection of invasive aspergillosis (IA), enabling timely treatment and improving patient survival rates. The kit is designed for simple and convenient operation, offering rapid and sensitive detection, thus serving as an effective tool for quantitative detection of GM antigen.

Career Highlights

Shuanzhu Zhai is associated with Dynamiker Biotechnology (Tianjin) Co., Ltd., where he continues to advance his research and development efforts. His work has positioned him as a key figure in the biotechnology sector, contributing to the enhancement of diagnostic methodologies.

Collaborations

Shuanzhu Zhai collaborates with notable colleagues such as Chunlong Liu and Jie Peng. Their combined expertise fosters innovation and drives the development of new technologies in the field.

Conclusion

Shuanzhu Zhai's contributions to biotechnology, particularly through his patented innovations, highlight the importance of early detection in medical diagnostics. His work not only improves patient outcomes but also sets a standard for future developments in the field.